|
3.2 Prévention - Obésité
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
FDA Publishes List of Surrogate Endpoints Used in Drug Approvals [RAPS]
|
|
|
|
|
|
The
list, which separates adult and pediatric endpoints, does not include
composite endpoints that are a combination of biomarker surrogate
endpoints and clinical endpoints. The table also does not include
surrogate endpoints that may have been accepted for past drug
development programs but are no longer acceptable as an endpoint to
support registration.
|
|
|
|
|
|
|
Implementing the 21st Century Cures Act: An Update from FDA and NIH - Oral Statement [FDA]
|
|
|
|
|
|
The
use of surrogates for cancer can put promising treatments into the
hands of high-risk patients years before they would’ve been available
using previous endpoints, and, in some cases, increase the likelihood of
a achieving a long-term remission. To advance this science, today we’re
meeting one of our commitments under the Cures Act related to
surrogates.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
Paying for therapies that cure: innovative solutions needed [STAT]
|
|
|
|
|
|
To
be sure, contracts designed around an annuity approach or HealthCoin
won’t be the magic bullet that aligns incentives, but they do represent
the kind of beyond-the-system thinking needed as we move to a world
where tomorrow’s innovation looks different than yesterday’s
breakthroughs.
|
|
|
|
|
|
|
Pembrolizumab for classical hodgkin lymphoma [NICE]
|
|
|
|
|
|
After
considering the feedback from consultation, the Appraisal Committee has
prepared a Final Appraisal Document (FAD) on Pembrolizumab for treating
relapsed or refractory classical Hodgkin lymphoma and submitted it to
the Institute.
|
|
|
|
|
|
|
NICE Recommends Pembrolizumab for Untreated PD-L1-positive Metastatic NSCLC [ESMO]
|
|
|
|
|
|
The
most plausible cost-effectiveness estimate for pembrolizumab compared
with chemotherapy is within the range NICE normally considers acceptable
for an end-of-life treatment. Therefore, it can be recommended as an
option for untreated metastatic PD‑L1-positive (with at least a 50%
tumour proportion score) NSCLC if treatment is stopped after 2 years.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Third Retraction for Harvard Cancer Biologist [The Scientist]
|
|
|
|
|
|
The
paper, led by Harvard Medical School biologist Sam Lee, is among
several publications from his group to be retracted. Molecular Cell and
the Journal of Biological Chemistry have each withdrawn one of Lee’s
studies in recent years due to “inappropriately assembled” data and
figure manipulation, respectively.
|
|
|
|
|
|
|
Nature cancer paper that raised animal welfare concerns is retracted [Retraction Watch]
|
|
|
|
|
|
“Selective
killing of cancer cells by a small molecule targeting the stress
response to ROS” has been cited 577 times, according to Clarivate
Analytics’ Web of Science — making it a “highly cited paper,” meaning it
was ranked in the top 1 percent of all papers in its field for the year
it was published. It’s been cited 257 times since its last correction
was published in September 2015.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|